Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
Mike Gladstone
Advertisement
Articles by Mike Gladstone
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1s Could Replace the Need for Knee Replacement Surgery
2
Q&A: Pharmacists Can Address ADA Standards Across All Settings
3
Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides
4
HHS Using AI Initiative to Uncover Health Care Fraud, Waste
5